Gene
SETD2
SETD2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (9), Actionable biomarkers (2), Trial mentions (22), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention SETD2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 3 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 1 of 8,738 | 0.01% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 2 of 8,597 | 0.02% | not measured | |
| 2023 | 3 of 8,275 | 0.04% | 11 of 11,460 | 0.10% |
| 2022 | 1 of 8,285 | 0.01% | 15 of 13,598 | 0.11% |
| 2021 | 0 of 8,692 | 0.00% | 17 of 15,045 | 0.11% |
| 2020 | 0 of 7,640 | 0.00% | 13 of 14,459 | 0.09% |
| 2019 | 1 of 7,300 | 0.01% | 10 of 12,159 | 0.08% |
| 2018 | 1 of 6,927 | 0.01% | 6 of 11,854 | 0.05% |
| 2017 | 1 of 6,558 | 0.02% | 7 of 11,595 | 0.06% |
Showing 10 of 37 years.
Assay-provider ledger (9)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| AB Applied Biosystems | Reagent supplier | Clinical validation | 1 | February 04, 2025 |
| Novozymes (Nanjing, China) | Reagent supplier | Clinical validation | 1 | February 04, 2025 |
| Solarbio | Reagent supplier | Clinical validation | 1 | February 04, 2025 |
| TAKARA | Reagent supplier | Clinical validation | 1 | February 04, 2025 |
| TECHNE | Reagent supplier | Clinical validation | 1 | February 04, 2025 |
Showing 5 of 9 assay-provider companies.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| SETD2 deletion | Wee1 Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
| SETD2 oncogenic mutation | Wee1 Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (22)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT01814449 | Trial biospecimen (AACT) |
| NCT02576665 | Trial eligibility (AACT) |
| NCT00117013 | Trial eligibility (AACT) |
| NCT05121103 | Trial eligibility (AACT) |
| NCT06458244 | Trial eligibility (AACT) |
Showing 5 of 22 trial mentions.
Target-disease associations (725)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abnormal facial shape | phenotype | genomics england |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
| Acheiropodia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Acromesomelic dysplasia, Grebe type | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Acromesomelic dysplasia, Hunter-Thomson type | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 725 associations.
Vendor sourcing (71)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Frameshift: predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple path... | View ClinVar record SCV002012007.1 |
| AIDS Malignancy Consortium | Trial sponsor | Mentioned in trial textTrial free-text mention | HIF1 | View trial NCT00686842 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.3860A>C (p.Q1287P) alteration is located in exon 3 (coding exon 3) of the SETD2 gene. This alteration results from a A to C substitution at nucleotide ... | View ClinVar record SCV000742261.5 |
| Astrazeneca Plc | Trial collaborator | Mentioned in trial textTrial free-text mention | HIF1 | View trial NCT02506816 |
| Baylor College of Medicine | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV002515302.1 |
Showing 5 of 71 sourcing records.
Trial-cited literature (120)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study. | Blood advances | 2025 | 14 |
| Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146. | Journal for immunotherapy of cancer | 2024 | 17 |
| A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). | Cancer research communications | 2024 | 12 |
| The evolution of lung cancer and impact of subclonal selection in TRACERx. | Nature | 2023 | 243 |
| Genomic-transcriptomic evolution in lung cancer and metastasis. | Nature | 2023 | 173 |
Showing 5 of 120 papers.
Protein variant mentions (75)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A1124V | 1 | 2013 | PMID 24267886 |
| p.A197V | 1 | 2015 | PMID 25741868 |
| p.A2324S | 1 | 2015 | PMID 25741868 |
| p.A50T | 1 | 2015 | PMID 25741868 |
| p.A848V | 2 | 2015 to 2016 | PMID 26467025, PMID 25741868 |
Showing 5 of 75 variants.
Literature-extracted relations (16)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Disease Progression | Disease | associate |
Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study. | 2025 |
| Angina, Stable | Disease | associate |
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). | 2024 |
| Carcinoma, Renal Cell | Disease | associate |
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). | 2024 |
| Neoplasms | Disease | associate |
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). | 2024 |
| Thymoma | Disease | associate |
Genomic characterization of thymic epithelial tumors in a real-world dataset. | 2023 |
Showing 5 of 16 relation assertions.
Organizations publishing (230)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 16 | 2013 to 2024 |
| The University of Texas System | Academic | 9 | 2013 to 2023 |
| Dana-Farber Cancer Institute | Other | 8 | 2014 to 2025 |
| Government of the United States of America | Government | 8 | 2014 to 2024 |
| Novant Health | Hospital | 7 | 2012 to 2022 |
Showing 5 of 230 organizations.
Where SETD2 appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
635 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.